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Classification 
Note: Hereditary colorectal cancers can be broadly 
classified into three types:  
1- Familial adenomatous polyposis (FAP): 
characterized by the development of hundreds of 
polyps at a very early age, due to mutations in the APC 
gene. 
2- Attenuated familial adenomatous polyposis (AFAP): 
Fewer polyps, and later onset of cancer than FAP. The 
difference is due to extreme 5' mutations in APC gene. 
3- Hereditary nonpolyposis colon cancer (HNPCC) or 
Lynch syndrome: develops without the polyps, due to 
germline mutations in genes intervening in the repair of 
DNA mismatches occurring during replication (mostly 
hMSH2 and hMLH1 on 2p16 and 3p21 respectively). 




75% colorectal cancers occur sporadically. 25% are 
associated with family history. 5-6% through genetic 
mutations. 85% arise from chromosomal instability, 
15% due to microsatellite instability. Most arise from 
adenomatous polyps. 
History with ulcerative colitis, breast, uterine and 
ovarian cancers. Personal or familial history of colon 
cancer increases the risk (23% of all colorectal 
cancers). 
High fat diet, obesity, smoking may also increase th  
risk. 
Epidemiology 
Colorectal cancer is the third most frequent cancer in 
the world in both sexes and the third most frequent 
cause of cancer related deaths. 
Until age 50, men and women are susceptible at same 
levels, but after 50 years of age, men are more 
susceptible. 
Clinics 
The majority of colorectal cancers arise from pre-
existing adenomatous polyps. 
Pathology 
Dukes's staging system, modified by Astler-Coller. 
Detection through colonoscopy, flexible 
sigmoidoscopy, barium enema, chest x-ray, faecal 
occult blood testing (FOBT). 
Treatment 
Surgery is the most common method. 
- For colon cancer, the tumour together with a small 
portion of the surrounding tissue is removed with the
adjacent lymph nodes. 
- For rectal cancer, rectum is totally removed and 
replaced with colostomies. 
After surgery, micrometastasis can be experienced, 
which requires chemotherapy to destroy the metastatic 
cells (adjuvant chemotherapy). 5FU is the most 
frequently used drug. Radiotherapy may be used for 
rectal cancer, but it is not useful in colon cancer. 
Prognosis 
Survival, although improving is not much more than 
50% after 5 years, depending mainly of the stage of 
tumour growth at the time of diagnosis. Metastasis  
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resulting from penetration of the tumor through the 
bowel wall of the colon is very common with lymph 
node involvement. Patients with early colon cancer can
survive with surgery (more than 80%). For patients 
with metastasis, 5 year survival rate is less than 10%. 
Genetic alterations have been studied in relation t 
prognosis with contradictory results. Loss of 
heterozygosity (LOH) of chromosomes 18q and 17p 
and overexpression and mutation of the p53 gene result 
in poorer prognosis in primary cancer patients. 
Cytogenetics 
Cytogenetics morphological 
There are two types of colorectal cancers, according to 
the ploidy: 
- Aneuploid tumours showing numerous allelic losses; 
- Aneuploidy, loss and rearrangements of chromosome 
1p (about 70%), 5q (55%, loss of APC), 15q, 18q 
(65%, loss of DCC), 17p (80%, TP53), and 17q (30%); 
and abnormalities in 7q(25%) and 8p (55%). 
Reciprocal translocation t(5;10)(q22;q25), inv(5)(q22-
q31.3). 
Diploid tumours without frequent allelic losses. 
Genes involved and Proteins 
Note: A number of genes are known to be implicated in 
tumour progression in colorectal cancers. They are 
either oncogenes or tumour suppressor genes. A model 





16 exons, 10702 bp mRNA. 
Protein 
Tumour suppressor protein composed of 2843 amino 
acids; the APC interacts with the adherens junction 
proteins a and beta-catenin suggesting involvement in 
cell adhesion. APC may also inhibit the pathway 
regulated by the beta-catenin /Tcf complex. Other 
functions include anterior-posterior pattern formation, 
axis specification, cell cycle, cell migration, apopt sis, 
chromosome segregation and spindle assembly. 
Germinal mutations 
Point mutations in APC gene results in the generation 
of stop codons, small deletions, LOH, 1-2 bp insertions. 
Most mutations result in a truncated protein, mostly in 
the first half. Results in FAP and AFAP. 
Somatic mutations 
The APC gene is mutated in about 50% of sporadic 
colorectal tumours. Most mutations are frameshifts o  
nonsense mutations resulting in premature stop codons.  
Some mutations on beta-catenin have been described in 
tumours and cell lines without mutations in the APC 
gene. APC loss may also be due to interstitial deletion 
or mitotic recombination, LOH, and nonsense 
mutations. Most of the somatic mutations are clustered 
in the exon 15 in mutation cluster region (MCR). about 
20% of APC mutations are observed with mutation of 






Tumour suppressor has essential role in cell cycle 
regulation, in G1 DNA damage checkpoint. 5 highly-
conserved regions containing a transactivation domain, 
a DNA-binding domain, nuclear localization signals 
and a tetramerization domain. P53 is thus a 
transcriptional regulator regulating the transcription of 
genes whose products inhibit cell growth and 
proliferation and induce apoptosis. It is also called the 
guardian of the genome preventing cells from dividing 
before DNA damage is repaired. 
Somatic mutations 
Mutations of P53 are mostly located in exons 4 to 8 
with hotspots at codons 175, 245, 248, 273 and 282.
They can be either missense mutations, or non-sense, 
deletions, insertions and splicing mutations resulting in 
a truncated p53 protein. Mutant form of p53 is found to 
be overexpressed in primary colon cancer. p53 
mutation is observed in 40-50% of colorectal 
carcinomas, and is associated with aggressive 
carcinomas. p53 mutation or LOH of chromosome 17p 
is observed mostly in carcinoma rather then adenoma, 
in both familial and non-familial patients. 
80% of mutations result from deamination of 
methylated cytosine in CpG region of the gene (codons 




19 exons, 2524 bp mRNA. 
Protein 
Human homolog of E. coli DNA mismatch repair gene 
MutL. Defects observed in 30% of HNPCC. 
Germinal mutations 
Results in HNPCC. Deletion of codons 578 to 632 
(they constitute a single exon), deletion and 
frameshifts, nonsense mutations, insertions, truncated 
protein. Both of the genes should be impaired for 
phenotype to occur. Mutations give rise to 
microsatellite instability. 
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Somatic mutations 







Human homolog of E. coli MutS protein, functional in 
mismatch repair, defects observed in about 60% of 
HNPCC. 
Germinal mutations 







Functions in mismatch binding. 
Germinal mutations 
Deletion (of CT at nucleotide 3052 in exon 4), 






Functional in mismatch repair. 
Germinal mutations 
In frame deletion, out of frame deletion, point 





10 exons, 4259 bp mRNA. 
Protein 
The protein has role in regulation of beta-catenin 
pathway. 
Somatic mutations 
Axin2 is mutated in MMR deficient CRC cells. The 
mutations result in the stabilization of beta catenin and 
activation of the T-cell factor signaling. Also epigenetic 




10 exons, 3276 bp mRNA. 
Protein 
Tumor suppressor serine-threonine kinase, functions in 
cell cycle arrest. Mutations result in Peutz-Jeghers 
syndrome. 
Germinal mutations 
Nonsense, missense, frameshift mutations. 
Somatic mutations 
Mutations give rise to Peutz-Jeghers syndrome, which 




9 exons, 3417bp mRNA. 
Protein 
Tumor suppressor protein, which negatively regulates 
AKT/PKB signaling. Also known as 'mutated in 
multiple advanced cancers' since mutations are found in 
many cancers. The protein is a phosphatidylinositol-
3,4,5-trisphosphate 3-phosphatase, removing 
phosphates from serine, tyrosine and threonine. 
Germinal mutations 
Results in Cowden Syndrome, a cancer prone 
syndrome and Bannayan-Riley-Ruvalcaba Syndrome. 
Somatic mutations 
Somatic mutations of PTEN are a result of MLH1-
MSH2 deficiency in HNPCC patients. Frameshift 
mutations in MMR deficient cells. Nonsense, missense, 




13 exons, 3616bp mRNA. 
Protein 
Transmembrane serine-threonine kinase, type1 
receptor. 
Germinal mutations 





13 exons, 3202 bp mRNA. 
Protein 
Protein is coded from 11 exons. A tumor suppressor, 
functioning in TGFbeta signaling, mediating signals 
from cell surface to nucleus. 
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Germinal mutations 
Result in juvenile polyps. 
Somatic mutations 
Deletion of SMAD4 results in epithelial cancers. 
Minimally lost region on chromosome 18q21, 
containing the SMAD4 gene is found in colorectal 
cancers. 4-basepair deletion in exon 9 of SMAD4 is 




16 exons, 1839 bp mRNA. 
Protein 
DNA glycosylase. Functions in oxidative DNA damage 
repair (base excision repair), nicks A-G mismatches, as 
well as A-8oxoG and A-C mismatches. 
Germinal mutations 
Tyr82-Cys and Gly253 -Asp transitions affect 
glycosylase activity, resulting in APC mutations in 
somatic cells. Nonsense mutations, missense and 
truncated protein mutations. Mutations cause 93-fold 




29 exons, 4609 bp mRNA. 
Protein 
DCC is thought to be receptor for neptin-1 (axonal 
chemoattractant). In absence of ligand, it induces 
apoptosis but when neptin-1 is bound, it prevents 
apoptosis. 
Germinal mutations 
Chromosome 18 sequences are frequently (74%) lost in 
colorectal carcinoma. Loss of DCC is mostly observed 
in metastatic cancers. 





Ki-ras belongs to the ras gene family containing also 
Ha-ras and N-ras; they encode for closely related 21-
kDa (189 amino acids) GTP-binding proteins with a 
role in growth signal transduction; oncogenes. 
Somatic mutations 
These genes are activated by point mutations at codons 
12, 13 and 61, and, in the case of colorectal cancers, 
Ki-ras is mutated on codons 12 or 13 in about 40% of 
the cases. 
Homozygous deletion of 5' end, point mutation in one 
of the introns (for example intron 13), probably 
interfering with splicing, DNA insertions. 
To be noted 
- The RER+ sporadic colon cancers are mostly diploid, 
without LOH, with few mutations of p53 and APC and 
right-sided; they contain mutations in repetitive coding 
sequences of a number of genes such as the TGFbeta 
type II receptor, the receptor of the Insulin-like growth 
factor and the BAX gene implicated in apoptosis.  
- The RER- are polyploid, with LOH (5q, 17p, 18q), 
mutations in p53, and more often left-sided, they have a 
worse prognosis. 
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